Browsing Tag: PharmaIndia Weekly October 12

AstraZeneca’s Camizestrant Clears India’s SEC Review The Story: AstraZeneca’s camizestrant has received a positive SEC recommendation in India for HR-positive, HER2-negative advanced breast cancer wit...